What we have learned from trials of immunomodulatory agents in rheumatoid arthritis: Future directions

Drugs of Today

Volumn 35, Issue 4-5, 1999, Pages 327-351

  Schulze Koops, Hendrik ^a   Burkhardt, Harald ^a   Kalden, Joachim R ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[[4 (4 CHLOROPHENOXY)PHENYL]SULFONYL]METHYL]TETRAHYDRO 2H PYRAN 4 CARBOHYDROXAMIC ACID; ALEMTUZUMAB; AMINOGUANIDINE; BASILIXIMAB; CELL ADHESION MOLECULE; CHEMOKINE; CYCLOSPORIN; CYTOKINE; GI 168; IMMUNOMODULATING AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 7; MONOCLONAL ANTIBODY CD5; N(G) METHYLARGININE; NITRIC OXIDE; OKT 4; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 4; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; CLINICAL TRIAL; CONFERENCE PAPER; HELPER CELL; HUMAN; IMMUNOMODULATION; INFLAMMATION; NONHUMAN; PATHOGENESIS; RECEPTOR UPREGULATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032797030     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.4-5.552208     Document Type: Conference Paper

References (172)

1. Cush, J.J., Lipsky, P.E. Cellular basis for rheumatoid inflammation. Clin Orthop 1991, 265: 9-22.
2. Cush, J.J., Lipsky, P.E. The immunopathogenesis of rheumatoid arthritis: The role of cytokines in chronic inflammation. Clin Aspects Autoimmun 1987, 1: 2-12.
3. Harris, E.D. Rheumatoid arthritis: Pathophysiology and implications for treatment. New Engl J Med 1990, 322: 1277-89.
4. Cush, J.J., Lipsky, P.E. Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum 1988, 31: 1230-8.
5. Van Boxel, J.A., Paget, S.A. Predominantly T-cell infiltrate in rheumatoid synovial membranes. New Engl J Med 1975, 293: 517-20.
6. Strober, S., Tanay, A., Field, E. et al. Efficacy of total lymphoid irradiation in ntractable rheumatoid arthritis. A double-blind, randomized trial. Ann Intern Med 1985, 102: 441-9.
7. Paulus, H.E., Machleder, H.I., Levine, S., Yu, D.T., MacDonald, N.S. Lymphocyte involvement in rheumatoid arthritis. Studies during thoracic duct drainage. Arthritis Rheum 1977, 20: 1249-62.
8. Panayi, G.S., Tugwell, P. The use of cyclosporin A in rheumatoid arthritis: Conclusions of an international review. Br J Rheumatol 1994, 33: 967-9.
9. Calin, A., Elswood, J., Klouda, P.T. Destructive arthritis, rheumatoid factor, and HLA-DR4. Susceptibility versus severity, a case-control study. Arthritis Rheum 1989, 32: 1221-5.
10. Winchester, R. The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol 1994, 56: 389-466.
11. Lipsky, P.E., Davis, L.S., Cush, J.J., Oppenheimer-Marks, N. The role of cytokines in the pathogenesis of rheumatoid arthritis. Springer Semin Immunopathol 1989, 11: 123-62.
12. Firestein, G.S., Tsai, V., Zvaifler, N.J. Cellular immunity in the joints of patients with rheumatoid arthritis and other forms of chronic synovitis. Rheum Dis Clin North Am 1987, 13: 191-213.
13. Saxne, T., Palladino, M.A., Jr., Heinegard, D., Talal, N., Wollheim, F.A. Detection of tumor necrosis factor a but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988, 31: 1041-5.
14. Eastgate, J.A., Symons, J.A., Wood, N.C., Grinlinton, F.M., Di Giovine, F.S., Duff, G.W. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet 1988, 2: 706-9.
15. Graeve, L., Baumann, M., Heinrich, P.C. Interleukin-6 in autoimmune diseases. Clin Investigator 1993, 71: 664-71.
16. Husby, G., Williams, R.C., Jr. Synovial localization of tumor necrosis factor in patients with rheumatoid arthritis. J Autoimmun 1988, 1: 363-71.
17. Tetta, C., Camussi, G., Modena, V., Di Vittorio, C., Baglioni, C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990, 49: 665-7.
18. Ranges, G.E., Sriram, S., Cooper, S.M. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 1985, 162: 1105-10.
19. Wofsy, D., Seaman, W.E. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol 1987, 138: 3247-53.
20. Arnett, F.C., Edworthy, S.M., Bloch, D.A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31: 315-24.
21. Schulze-Koops, H., Davis, L.S., Kavanaugh, A.F., Lipsky, P.E. Elevated cytokine messenger RNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activation. Arthritis Rheum 1997, 40: 639-47.
22. Firestein, G.S., Paine, M.M. Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. Am J Pathol 1992, 140: 1309-14.
23. Shingu, M., Nagai, Y., Isayama, T., Naono, T., Nobunaga, M. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993, 94: 145-9.
24. Kalden, J.R., Breedveld, F.C., Burkhardt, H., Burmester, G.R. Immunological treatment of autoimmune diseases. Adv Immunol 1998, 68: 333-418.
25. Hafler, D.A., Weiner, H.L. Oral tolerance for the treatment of autoimmune diseases. In: Novel Therapeutic Agents for the Treatment of Autoimmune Diseases. V. Strand, D.L. Scott and L.S. Simon (Eds.). Dekker: New York 1997, 210-20.
26. Sieper, J., Kary, S., Sorensen, H. et al. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996, 39: 41-51.
27. Roessler, B.J., Allen, E.D., Wilson, J.M., Hartman, J.W., Davidson, B.L. Adenoviral-mediated gene transfer to rabbit synovium in vivo. J Clin Invest 1993, 92: 1085-92.
28. Ghivizzani, S.C., Kang, R., Muzzonigro, T. et al. Gene therapy for arthritis - Treatment of the first three patients. Arthritis Rheum 1997, 40: S223.
29. Fujisawa, K., Asahara, H., Okamoto, K., et al. Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice. J Clin Invest 1996, 98: 271-8.
30. Adorini, L., Guery, J.C., Trembleau, S. Manipulation of the Th1/Th2 cell balance: An approach to treat human autoimmune diseases? Autoimmunity 1996, 23: 53-68.
31. Saoudi, A., Kuhn, J., Huygen, K. et al. TH2-activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. Eur J Immunol 1993, 23: 3096-103.
32. + T-cell subset that inhibits this autoimmune potential. J Exp Med 1993, 177: 627-36.
33. Khoury, S.J., Hancock, W.W., Weiner, H.L. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor β, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 1992, 176: 1355-64.
34. Marcelletti, J.F., Ohara, J., Katz, D.H. Collagen-induced arthritis in mice. Relationship of collagen-specific and total IgE synthesis to disease. J Immunol 1991, 147: 4185-91.
35. van der Veen, R.C., Stohlman, S.A. Encephalitogenic Th1 cells are inhibited by Th2 cells with related peptide specificity: relative roles of interleukin (IL)-4 and IL-10. J Neuroimmunol 1993, 48: 213-20.
36. Miltenburg, A.M., van Laar, J.M., de Kuiper, R., Daha, M.R., Breedveld, F.C. T-cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scand J Immunol 1992, 35: 603-10.
37. Simon, A.K., Seipelt, E., Sieper, J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA 1994, 91: 8562-6.
38. Quayle, A.J., Chomarat, P., Miossec, P., Kjeldsen-Kragh, J., Førre, Ø., Natvig, J.B. Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0) cytokine patterns. Scand J Immunol 1993, 38: 75-82.
39. Schulze-Koops, H., Lipsky, P.E., Kavanaugh, A.F., Davis, L.S. Elevated Th1 or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis: modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol 1995, 155: 5029-37.
40. Wilde, D.B., Marrack, P., Kappler, J., Dialynas, D.P., Fitch, F.W. Evidence implicating L3T4 in class II MHC antigen reactivity: monoclonal antibody GK1.5 (anti-L3T4a) blocks class II MHC antigen-specific proliferation, release of lymphokines, and binding by clones of murine helper T-lymphocyte lines. J Immunol 1983, 131: 2178-83.
41. Tsygankov, A.Y., Broker, B.M., Guse, A.H. et al. Preincubation with anti-CD4 influences activation of human T-cells by subsequent co-cross-linking of CD4 with CD3. J Leukocyte Biol 1993, 54: 430-8.
42. Waldor, M.K., Sriram, S., Hardy, R. et al. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science 1985, 227: 415-7.
43. Wofsy, D., Seaman, W.E. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med 1985, 161: 378-91.
44. Shizuru, J.A., Taylor-Edwards, C., Banks, B.A., Gregory, A.K., Fathman, C.G. Immunotherapy of the nonobese diabetic mouse: Treatment with an antibody to T-helper lymphocytes. Science 1988, 240: 659-62.
45. Benjamin, R.J., Waldmann, H. Induction of tolerance by monoclonal antibody therapy. Nature 1986, 320: 449-51.
46. Shizuru, J.A., Alters, S.E., Fathman, C.G. Anti-CD4 monoclonal antibodies in therapy: Creation of nonclassical tolerance in the adult. Immunol Rev 1992, 129: 105-30.
47. Waldmann, H., Cobbold, S. The use of monoclonal antibodies to achieve immunological tolerance. Immunol Today 1993, 14: 247-51.
48. Horneff, G., Burmester, G.R., Emmrich, F., Kalden, J.R. Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991, 34: 129-40.
49. Moreland, L.W., Bucy, P.R., Jackson, B., James, T., Koopman, W.J. Long-term (5 years) follow-up of rheumatoid arthritis patients treated with a depleting anti-CD4 monoclonal antibody, cM-T412. Arthritis Rheum 1996, 39: S244.
50. Moreland, L.W., Pratt, P.W., Mayes, M.D. et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995, 38: 1581-8.
51. van der Lubbe, P.A., Dijkmans, B.A., Markusse, H.M., Nassander, U., Breedveld, F. C. A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 1995, 38: 1097-106.
52. Tak, P.P., van der Lubbe, P.A., Cauli, A. et al. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum 1995, 38: 1457-65.
53. + cells. J Immunol 1986, 137: 3414-9.
54. + cells. J Immunol 1988, 140: 713-6.
55. Brostoff, S.W., Mason, D.W. Experimental allergic encephalomyelitis: Successful treatment in vivo with a monoclonal antibody that recognizes T-helper cells. J Immunol 1984, 133: 1938-42.
56. Burkhardt, K., Charlton, B., Mandel, T.E. An increase in the survival of murine H-2-mismatched cultured fetal pancreas allografts using depleting or nondepleting anti-CD4 monoclonal antibodies, and a further increase with the addition of cyclosporine. Transplantation 1989, 47: 771-5.
57. Qin, S.X., Wise, M., Cobbold, S.P. et al. Induction of tolerance in peripheral T-cells with monoclonal antibodies. Eur J Immunol 1990, 20: 2737-45.
58. Hutchings, P., O'Reilly, L., Parish, N.M., Waldmann, H., Cooke, A. The use of a non-depleting anti-CD4 monoclonal antibody to re-establish tolerance to beta cells in NOD mice. Eur J Immunol 1992, 22: 1913-8.
59. Choy, E.H., Pitzalis, C., Cauli, A. et al. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic closing regimens. Arthritis Rheum 1996, 39: 52-6.
60. Rep, M.H., van Oosten, B.W., Roos, M.T., Ader, H.J., Polman, C.H., van Lier, R.A. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T-cells but does not affect IFN-γ secreting TH1 cells in humans. J Clin Invest 1997, 99: 2225-31.
61. Volk, H.D., Siegling, A., Platzer, C., Brock, J., Emmrich, F., Lehmann, M. Tolerance induction by anti-CD4 MAB treatment in a rat kidney transplantation model. Transplant Proc 1994, 26: 3155-6.
62. Schwitalle, Y., Laub, R., Wenk, K., Voll, R., Emmrich, F. The anti-CD4 monoclonal antibody Max.16H5 induces an increase of intracellular IL-4 in human T-cell clones. Immunobiology 1996, 196: 21.
63. Schulze-Koops, H., Davis, L.S., Haverty, P., Wacholtz, M.C., Lipsky, P.E. Reduction of activity in patients with rheumatoid arthritis after treatment with a non-depleting monocloncal antibody to CD4. Arthritis Rheum 1997, 40: S191.
64. Horneff, G., Guse, A.H., Schulze-Koops, H., Kalden, J.R., Burmester, G.R., Emmrich, F. Human CD4 modulation in vivo induced by antibody treatment. Clin Immunol Immunopathol 1993, 66: 80-90.
65. Morel, P., Nicolas, J.F., Wijdenes, J., Revillard, J.P. Down-regulation of lymphocyte CD4 antigen expression by administration of anti-CD4 monoclonal antibody. Clin Immunol Immunopathol 1992, 64: 248-53.
66. Levy, R., Weisman, M., Wiesenhutter, C. et al. Results of a placebo-controlled multicenter trial using a primatized non-depleting, anti-CD4 monocloncal antibody in the treatment of rheumatoid arthritis. Arthritis Rheum 1996, 39: S122.
67. Panayi, G.S., Choy, E.H.S., Connolly, D.J.A., et al. T-cell hypothesis in rheumatoid arthritis (RA) tested by humanized non-depleting anti-CD4 monocloncal antibody (MAb) treatment I: Suppression of disease activity and acute phase response. Arthritis Rheum 1996, 39: S244.
68. + B-cells and the immune system. Immunol Lett 1993, 38: 159-66.
69. Cush, J.J. Anti-CD5/Ricin A chain immunoconjugate therapy in rheumatoid arthritis. In: Novel Therapeutic Agents for the Treatment of Autoimmune Diseases. V. Strand, D.L. Scott and L.S. Simon (Eds.). Dekker: New York 1997, 11-24.
70. Byers, B.S., Caperton, E., Ackerman, S., Shephard, J., Scannon, P.J. Modification of the immune system in patients with rheumatoid arthritis treated with anti-CD5 ricin A chain immunotoxin. FASEB J 1989, 3: A1122.
71. Strand, V., Lipsky, P.E., Cannon, G.W. et al. Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1993, 36: 620-30.
72. Olsen, N.J., Brooks, R.H., Cush, J.J. et al. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum 1996, 39: 1102-8.
73. Kirkham, B.W., Pitzalis, C., Kingsley, G.H. et al. Monoclonal antibody treatment in rheumatoid arthritis: The clinical and immunological effects of a CD7 monoclonal antibody. Br J Rheumatol 1991, 30: 459-63.
74. Kirkham, B.W., Thien, F., Pelton, B.K. et al. Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 1992, 19: 1348-52.
75. Kyle, V., Coughlan, R.J., Tighe, H., Waldmann, H., Hazleman, B.L. Beneficial effect of monoclonal antibody to interleukin-2 receptor on activated T-cells in rheumatoid arthritis. Ann Rheum Dis 1989, 48: 428-9.
76. Thasia, G., Woodworth, T.G., Parker, K. Early clinical studies of IL-2-fusion toxin in patients with severe rheumatoid arthritis, recent-onset insulin-dependent diabetes mellitus, and psoriasis. In: Novel Therapeutic Agents for the Treatment of Autoimmune Diseases. V. Strand, D.L. Scott and L.S. Simon (Eds.). Dekker: New York 1997, 25-40.
77. Moreland, L.W., Sewell, K.L., Trentham, D.E. et al. Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension. Arthritis Rheum 1995, 38: 1177-86.
78. Hale, G., Xia, M.Q., Tighe, H.P., Dyer, M.J., Waldmann, H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990, 35: 118-27.
79. Brett, S., Baxter, G., Cooper, H., Johnston, J.M., Tite, J., Rapson, N. Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H. Immunology 1996, 88: 13-9.
80. Johnston, J.M., Speer, W.R. Treatment of rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H. In: Early Decisions in DMARD Therapy. III. Biologic Agents in Autoimmune Diseases. Arthritis Foundation: Atlanta, Georgia 1994, 155-65.
81. Springer, T.A. Adhesion receptors of the immune system. Nature 1990, 346: 425-34.
82. Carlos, T.M., Harlan, J.M. Membrane proteins involved in phagocyte adherence to endothelium. Immunol Rev 1990, 114: 5-28.
83. Strober, S., Holoshitz, J. Mechanisms of immune injury in rheumatoid arthritis: Evidence for the involvement of T-cells and heat-shock protein. Immunol Rev 1990, 118: 233-55.
84. Kavanaugh, A.F., Lightfoot, E., Lipsky, P.E., Oppenheimer-Marks, N. The role of CD11/CD18 in adhesion and transendothelial migration of T-cells: analysis utilizing CD18 deficient T-cell clones. J Immunol 1991, 146: 4149-56.
85. Oppenheimer-Marks, N., Davis, L.S., Bogue, D.T., Ramberg, J., Lipsky, P.E. Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T-lymphocytes. J Immunol 1991, 147: 2913-21.
86. Wacholtz, M.C., Patel, S.S., Lipsky, P.E. Leukocyte function-associated antigen 1 is an activation molecule for human T-cells. J Exp Med 1989, 170: 431-48.
87. Kavanaugh, A.F., Davis, L.S., Nichols, L.A. et al. Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994, 37: 992-9.
88. Kavanaugh, A.F., Davis, L.S., Jain, R.I., Nichols, L.A., Norris, S.H., Lipsky, P.E. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol 1996, 23: 1338-44.
89. Cosimi, A.B., Conti, D., Delmonico, F.L. et al. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol 1990, 144: 4604-12.
90. Lipsky, P.E., Kavanaugh, A.F., Schulze-Koops, H., Davis, L.S. Adhesion molecules as targets for therapy in rheumatoid arthritis. In: New Targets in Inflammation. Inhibitors of COX-2 or Adhesion Molecules. N. Bazan, J. Botting and J. Vane (Eds.). Kluwer Academic Publishers: Dordrecht 1996, 139-44.
91. Paulus, H.E., Egger, M.J., Ward, J.R., Williams, H.J., the Cooperative Systemic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990, 33: 477-84.
92. Pinals, R.S., Masi, A.T., Larsen, R.A. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24: 1308-15.
93. Davis, L.S., Kavanaugh, A.F., Nichols, L.A., Lipsky, P.E. Induction of persistent T-cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis. J Immunol 1995, 154: 3525-37.
94. Kavanaugh, A.F., Schulze-Koops, H., Davis, L.S., Lipsky, P.E. Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum 1997, 40: 849-53.
95. Brennan, F.M., Maini, R.N., Feldmann, M. TNF-α - A pivotal role in rheumatoid arthritis? Br J Rheumatol 1992, 31: 293-8.
96. Keffer, J., Probert, L., Cazlaris, H. et al. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J 1991, 10: 4025-31.
97. Williams, R.O., Feldmann, M., Maini, R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992, 89: 9784-8.
98. Elliott, M.J., Maini, R.N., Feldmann, M. et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993, 36: 1681-90.
99. Elliott, M.J., Maini, R.N., Feldmann, M. et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344: 1105-10.
100. Elliott, M.J., Maini, R.N., Feldmann, M., et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994, 344: 1125-7.
101. Rankin, E.C., Choy, E.H., Kassimos, D. et al. The therapeutic effects of an engineered human anti-tumour necrosis factor α antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995, 34: 334-42.
102. Kalden-Nemeth, D., Grebmeier, J., Antoni, C., Manger, B., Wolf, F., Kalden, J.R. NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-α monoclonal antibody therapy. Rheumatol Int 1997, 16: 249-55.
103. Lorenz, H.M., Antoni, C., Valerius, T. et al. In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996, 156: 1646-53.
104. Paleolog, E.M., Hunt, M., Elliott, M.J., Feldmann, M., Maini, R.N., Woody, J.N. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996, 39: 1082-91.
105. Tak, P.P., Taylor, P.C., Breedveld, F.C. et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39: 1077-81.
106. Joosten, L.A., Helsen, M.M., van de Loo, F.A., van den Berg, W.B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF-α, anti-IL-1 α/β, and IL-1Ra. Arthritis Rheum 1996, 39: 797-809.
107. Kavanaugh, A.F., Cush, J.J., St.Clair, E.W. et al. Anti-TNF-α monocloncal antibody (mAB) treament of rheumatoid arthritis (RA) patients with active disease on methrotrexate (MTX); results of double-blind, placebo-controlled multicenter trial. Arthritis Rheum 1996, 39: A575.
108. Sander, O., Rau, R., van Riel, P. et al. Neutralization of TNF by lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for three months: Results of a European phase II trial. Arthritis Rheum 1996, 39: 3242.
109. Cutolo, M., Kirkham, B., Bologna, C. et al. Loading/maintenance doses approach to neutralization of TNF by lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for three months: Results of a double-blind, placebo-controlled phase II trial. Arthritis Rheum 1996, 39: S243.
110. Hasler, F., van der Putte, L., Baudin, M. et al. Chronic TNF neutralization (up to 1 year) by lenercept (TNFR55-IgG1, Ro 45-2018) in patients with rheumatoid arthritis: Results of an open-label extension of a double-blind single dose phase I study. Arthritis Rheum 1996, 39: S243.
111. Furst, D., Weisman, M., Paulus, H. et al. Neutralization of TNF by lenercept (TNFR55-IgG1, Ro 45-2018) on patients with rheumatoid arthritis treated for three months: Results of a US phase II trial. Arthritis Rheum 1996, 39: S243.
112. Charles, P.J., Elliott, M.J., Feldmann, M. Development of anti-dsDNA antibodies in patients with rheumatoid arthritis treated with a chimeric monoclonal antibody to TNF-α. EULAR J 1995, 24: B114.
113. Campion, G.V., Lebsack, M.E., Lookabaugh, J., Gordon, G., Catalano, M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 1996, 39: 1092-101.
114. Bresnihan, B., Lookabaugh, J., Witt, K., Musikic, P. Treatment with recombinant human interleukin-1 receptor antagonist (rhUL-1ra) in rheumatoid arthritis (RA): Results of a randomized double-blind, placebo-controlled multicenter trial. Arthritis Rheum 1996, 39: S73.
115. Watt, I., Cobby, M. Recombinant human IL-1 receptor antagonist (rhIL-1ra) reduces the rate of joint erosion in rheumatoid arthritis (RA). Arthritis Rheum 1996, 39: S123.
116. Wendung, D., Racadot, E., Wijdenes, J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993, 20: 259-62.
117. Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.A., Coffman, R.L. Two types of murine helper T-cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136: 2348-57.
118. Grewal, I.S., Flavell, R.A. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 1996, 153: 85-106.
119. Tivol, E.A., Schweitzer, A.N., Sharpe, A.H. Costimulation and autoimmunity. Curr Opin Immunol 1996, 8: 822-30.
120. Finck, B.K., Linsley, P.S., Wofsy, D. Treatment of murine lupus with CTLA4Ig. Science 1994, 265: 1225-7.
121. Webb, L.M., Walmsley, M.J., Feldmann, M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 costimulatory pathway: Requirement for both B7-1 and B7-2. Eur J Immunol 1996, 26: 2320-8.
122. Grewal, I.S., Foellmer, H.G., Grewal, K.D. et al. Requirement for CD40 ligand in costimulation induction, T-cell activation, and experimental allergic encephalomyelitis. Science 1996, 273: 1864-7.
123. Gerritse, K., Laman, J.D., Noelle, R.J. et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996, 1993: 2499-504.
124. Durie, F.H., Fava, R.A., Foy, T.M., Aruffo, A., Ledbetter, J.A., Noelle, R.J. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993, 261: 1328-30.
125. Rulifson, I.C., Sperling, A.I., Fields, P.E., Fitch, F.W., Bluestone, J.A. CD28 costimulation promotes the production of Th2 cytokines. J Immunol 1997, 158: 658-65.
126. Stuber, E., Strober, W., Neurath, M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T-helper 1 cells through the inhibition of interleukin-12 secretion. J Exp Med 1996, 183: 693-8
127. Daikh, D.I., Finck, B.K., Linsley, P.S., Hollenbaugh, D., Wofsy, D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997, 159: 3104-8
128. Sloan-Lancaster, J., Allen, P.M. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T-cell biology. Ann Rev Immunol 1996, 14: 1-27.
129. Sloan-Lancaster, J., Evavold, B.D., Allen, P.M. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993, 363: 156-9.
130. De Magistris, M.T., Alexander, J., Coggeshall, M. et al. Antigen analog-major histocompatibility complexes act as antagonists of the T-cell receptor. Cell 1992, 68: 625-34.
131. Evavold, B.D., Sloan-Lancaster, J., Allen, P.M. Antagonism of superantigen-stimulated helper T-cell clones and hybridomas by altered peptide ligand. Proc Natl Acad Sci USA 1994, 91: 2300-4.
132. Windhagen, A., Scholz, C., Hollsberg, P., Fukaura, H., Sette, A., Hafler, D.A. Modulation of cytokine patterns of human autoreactive T-cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995, 2: 373-80.
133. Karin, N., Mitchell, D.J., Brocke, S., Ling, N., Steinman, L. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon-γ and tumor necrosis factor α production. J Exp Med 1994, 180: 2227-37.
134. Brocke, S., Gijbels, K., Allegretta, M. et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996, 379: 343-6.
135. Smith, J.A., Tso, J.Y., Clark, M.R., Cole, M.S., Bluestone, J.A. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T-cell receptor signal and induce clonal anergy. J Exp Med 1997, 185: 1413-22.
136. Smith, J.A., Bluestone, J.A. T-cell inactivation and cytokine deviation promoted by anti-CD3 MABs. Curr Opin Immunol 1997, 9: 648-54.
137. Schwartz, R.H. A cell culture model for T-lymphocyte clonal anergy. Science 1990, 248: 1349-56.
138. Germann, T., Szeliga, J., Hess, H. et al. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci USA 1995, 92: 4823-7.
139. Germann, T., Bongartz, M., Dlugonska, H. et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 1995, 25: 823-9.
140. Germann, T., Hess, H., Szeliga, J., Rude, E. Characterization of the adjuvant effect of IL-12 and efficacy of IL-12 inhibitors in type II collagen-induced arthritis. Ann NY Acad Sci 1996, 795: 227-40.
141. Hess, H., Gately, M.K., Rude, E., Schmitt, E., Szeliga, J., Germann, T. High doses of interleukin-12 inhibit the development of joint disease in DBA/1 mice immunized with type II collagen in complete Freund's adjuvant. Eur J Immunol 1996, 26: 187-91.
142. Yokoi, H., Kato, K., Kezuka, T. et al. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12. Eur J Immunol 1997, 27: 641-6.
143. Trinchieri, G., Peritt, D., Gerosa, F. Acute induction and priming for cytokine production in lymphocytes. Cytokine Growth Factor Rev 1996, 7: 123-32.
144. Kasama, T., Strieter, R.M., Lukacs, N.W., Lincoln, P.M., Burdick, M.D., Kunkel, S.L. Interlevkin-10 expression and chemokine regulation during the evolution of murine type II collagen-induced arthritis. J Clin Invest 1995, 95: 2868-76.
145. Walmsley, M., Katsikis, P.D., Abney, E. et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996, 39: 495-503.
146. Joosten, L.A., Lubberts, E., Durez, P. et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997, 40: 249-60.
147. Williams, R.O., Ghrayeb, J., Feldmann, M., Maini, R.N. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995, 84: 433-9.
148. Williams, R.O., Mason, L.J., Feldmann, M., Maini, R.N. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994, 91: 2762-6.
149. Ku, G., Faust, T., Lauffer, L.L., Livingston, D.J., Harding, M.W. Interleukin-1β converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine 1996, 8: 377-86.
150. Moss, M.L., Jin, S.L., Becherer, J.D. et al. Structural features and biochemical properties of TNF-α converting enzyme (TACE). J Neuroimmunol 1997, 72: 127-9.
151. Moss, M.L., Jin, S.L., Milla, M.E. et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 1997, 385: 733-6.
152. Mohler, K.M. Regulating TNF bioactivity: Implications for new therapeutic strategies. In: ACR Basic Science Symposium: Cytokine Regulation and Intracellular Effects. 61st ACR National Scientific Meeting 1997.
153. Bucala, R. MIF rediscovered: Cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB J 1996, 10: 1607-13.
154. Calandra, T., Bernhagen, J., Metz, C.N. et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377: 68-71.
155. Mikulowska, A., Metz, C.N., Bucala, R., Holmdahl, R. Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. J Immunol 1997, 158: 5514-7.
156. Koch, A.E., Kunkel, S.L., Shah, M.R. et al. Growth-related gene product a. A chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol 1995, 155: 3660-6.
157. Robinson, E., Keystone, E.C., Schall, T.J., Gillett, N., Fish, E.N. Chemokine expression in rheumatoid arthritis (RA): Evidence of RANTES and macrophage inflammatory protein (MIP)-1β production by synovial T-cells. Clin Exp immunol 1995, 101: 398-407.
158. Plater-Zyberk, C., Hoogewerf, A.J., Proudfoot, A.E., Power, C.A., Wells, T.N. Effect of a CC chemokine receptor antagonist on collagen-induced arthritis in DBA/1 mice. immunol Lett 1997, 57: 117-20.
159. Gong, J.H., Ratkay, L.G., Waterfield, J.D., Clark-Lewis, I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-Ipr mouse model. J Exp Med 1997, 186: 131-7.
160. Wooley, P.H., Schaefer, C., Whalen, J.D., Dutcher, J.A., Counts, D.F. A peptide sequence from platelet factor 4 (CT-112) is effective in the treatment of type II collagen-induced arthritis in mice. J Rheumatol 1997, 24: 890-8.
161. Liew, F.Y. Regulation of lymphocyte functions by nitric oxide. Curr Opin Immunol 1995, 7: 396-9.
162. Zielasek, J., Jung, S., Gold, R., Liew, F.Y., Toyka, K.V., Hartung, H.P. Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J Neuroimmunol 1995, 58: 81-8.
163. McCartney-Francis, N., Allen, J.B., Mizel, D.E. et al. Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 1993, 178: 749-54.
164. Stefanovic-Racic, M., Meyers, K., Meschter, C., Coffey, J.W., Hoffman, R.A., Evans, C.H. N-monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum 1994, 37: 1062-9.
165. McInnes, I.B., Leung, B.P., Field, M. et al. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med 1996, 184: 1519-24.
166. Mudgett, J.S., Visco, D., Christian, A. Models of inflammatory disease in the inducible nitric oxide synthetase (NOS2) knock-out mouse. In: Xth Symp European League Against Rheumatism 1998, Abst 14.
167. Conway, J.G., Wakefield, J.A., Brown, R.H. et al. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med 1995, 182: 449-57.
168. Mudgett, J.S., Hutchinson, N.I., Chartrain, N.A. et al. Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum 1998, 41: 110-21.
169. Lindy, O., Konttinen, Y.T., Sorsa, T. et al. Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum 1997, 40: 1391-9.
170. Lollini, L., Haller, J., Eugui, E.M. et al. Disease modification by RS-130830, a collagenase-3 selective inhibitor, in experimental osteoarthritis (OA). Arthritis Rheum 1997, 40: S87.
171. Burmester, G.R. Protease inhibition: Focus on trocade. In: Xth Symp European League Against Rheumatism 1998, Abst 48.
172. Isaacs, J.D., Watts, R.A., Hazleman, B.L. et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 1992, 340: 748-52.